ARM Highlights Growth and Access Advances in Cell-Based Immuno-Oncology

Published in Alliance for Regenerative Medicine (April 2025 Preview)

A new whitepaper from the Alliance for Regenerative Medicine highlights key takeaways from a multi-stakeholder workshop on the future of cell-based immuno-oncology (IO). In 2024 alone, landmark approvals included AMTAGVI for melanoma and TECELRA for sarcoma, marking cell therapy’s expansion beyond blood cancers. The report emphasizes curative outcomes for many patients, increasing outpatient administration, and new regulatory pilots to streamline global development. With over 10,000 patients expected to be treated globally in 2025, the industry is rapidly scaling both access and innovation in adoptive cell therapies.

Read the full preview on ARM:

👉 Advancing Cancer Care Through Innovation in Cell-Based Immuno-Oncology

Images used are for illustrative purposes only and do not depict actual persons, products, or facilities. For full detail, refer to the original article via the provided link.